In the Matter of SHINE Technologies, LLC; SHINE Medical Isotope Production Facility; Direct and Indirect Transfers of License
The U.S. Nuclear Regulatory Commission (NRC) is issuing an order approving the license transfer application filed by SHINE Technologies, LLC, dated February 4, 2026, as supplemented on April 13, 2026. Specifically, the order approves the direct transfer of Construction Permit No. CPMIF-001 for the SHINE Medical Isotope Production Facility from SHINE Technologies, LLC to SHINE Chrysalis, LLC and a conforming license amendment. The order also approves the indirect transfer of control of the construction permit as a result of the establishment of SHINE Chrysalis Holdings, LLC as the direct parent company of SHINE Chrysalis, LLC. SHINE Chrysalis Holdings, LLC is a wholly owned subsidiary of Illuminated Holdings, Inc., the current parent company of SHINE Technologies, LLC.
What this item does
The short version, using the agency's own summary text.
The U.S. Nuclear Regulatory Commission (NRC) is issuing an order approving the license transfer application filed by SHINE Technologies, LLC, dated February 4, 2026, as supplemented on April 13, 2026. Specifically, the order approves the direct transfer of Construction Permit No. CPMIF-001 for the SHINE Medical Isotope Production Facility from SHINE Technologies, LLC to SHINE Chrysalis, LLC and a conforming license amendment. The order also approves the indirect transfer of control of the construction permit as a result of the establishment of SHINE Chrysalis Holdings, LLC as the direct parent company of SHINE Chrysalis, LLC. SHINE Chrysalis Holdings, LLC is a wholly owned subsidiary of Illuminated Holdings, Inc., the current parent company of SHINE Technologies, LLC.
Order; issuance.
Important dates
The dates that matter most for this item.
Published
April 30, 2026
Who published it
The agencies listed in the official filing.